← Back to Clinical Trials
Recruiting NCT03364803

NCT03364803 Collecting Information About Treatment Results for Patients With Cushing's Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03364803
Status Recruiting
Phase
Sponsor Memorial Sloan Kettering Cancer Center
Condition Cushing's Disease
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2017-11-28
Primary Completion 2026-11-28

Trial Parameters

Condition Cushing's Disease
Sponsor Memorial Sloan Kettering Cancer Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 14 Years
Max Age N/A
Start Date 2017-11-28
Completion 2026-11-28
Interventions
Cushing's QoL (Quality of Life Questionnaire)Nottingham Health Profile (NHP)Hospital Anxiety and Depression Scale (HADS)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes.

Eligibility Criteria

Inclusion Criteria: * Age 14 or older * Active or treated overt Cushing's (due to pituitary, ectopic, or adrenal tumor), mild adrenal Cushing's syndrome (MACS), or a silent corticotroph tumor * The diagnosis of CS or MACS will be made by the PI, based on the below Endocrine Society guidelines, the patient's clinical presentation, and the PI's judgment. * Diagnostic criteria for ACTH-dependent Cushing's are according to the Endocrine Society and European Society of Endocrinology guidelines and include: Elevated 24-hour urinary free cortisol (UFC), normal or elevated plasma ACTH, elevated midnight salivary cortisol levels, or classic dexamethasone suppression testing for CD (morning cortisol \> 5 ug/dL after 1 mg overnight of classic 2-day low dose test) and a pituitary lesion on MRI (in the case of pituitary Cushing's). If patient does not have any of these results, pathology of ACTH tumor may confirm presence of disease. * Diagnostic criterion for MACS is according to the European Soci

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology